Blood thinners are a leading cause of drug-related harm. Can the risk be lowered?
For decades, the blood thinner of choice was warfarin. Patients needed regular blood tests to constantly monitor and…
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), a global clinical-stage biopharmaceutical company focused…
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…